RhumbLine Advisers’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

RhumbLine Advisers’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,394	Closed	-$29K	–	3349
2022 Q1	$29K	Buy	17,394 +1,201	+7%	+$2.14K	﹤0.01%	2997
2021 Q4	$39K	Buy	16,193 +5,818	+56%	+$23.7K	﹤0.01%	2989
2021 Q3	$57K	Sell	10,375 -467	-4%	-$2.9K	﹤0.01%	3023
2021 Q2	$81K	Buy	+10,842	New	+$76.8K	﹤0.01%	2972

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RhumbLine Advisers's KLDO Position: Q2 2022 in Review

RhumbLine Advisers sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 17,394 shares — an estimated $29K sold.

RhumbLine Advisers first reported a position in KLDO in Q2 2021 and held it in 4 quarters. The position peaked at $81K in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

RhumbLine Advisers reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 17,394 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $29K.
RhumbLine Advisers first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's Kaleido Biosciences, Inc. Common Stock position peaked at $81K in Q2 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.